Caseware UK (AP4) 2023.0.135 2023.0.135 2023-07-312023-07-3122022-08-01falsetrue2trueThe members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.false 12118523 2022-08-01 2023-07-31 12118523 2023-07-31 12118523 2021-08-01 2022-07-31 12118523 2022-07-31 12118523 c:Director1 2022-08-01 2023-07-31 12118523 c:Director2 2022-08-01 2023-07-31 12118523 d:CurrentFinancialInstruments 2023-07-31 12118523 d:CurrentFinancialInstruments 2022-07-31 12118523 d:CurrentFinancialInstruments d:WithinOneYear 2023-07-31 12118523 d:CurrentFinancialInstruments d:WithinOneYear 2022-07-31 12118523 d:ShareCapital 2023-07-31 12118523 d:ShareCapital 2022-07-31 12118523 d:RetainedEarningsAccumulatedLosses 2023-07-31 12118523 d:RetainedEarningsAccumulatedLosses 2022-07-31 12118523 c:FRS102 2022-08-01 2023-07-31 12118523 c:AuditExemptWithAccountantsReport 2022-08-01 2023-07-31 12118523 c:FullAccounts 2022-08-01 2023-07-31 12118523 c:PrivateLimitedCompanyLtd 2022-08-01 2023-07-31 12118523 2 2022-08-01 2023-07-31 12118523 e:PoundSterling 2022-08-01 2023-07-31 iso4217:GBP xbrli:pure
Registered number: 12118523


AANW ANAESTHETICS LIMITED








UNAUDITED

FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 JULY 2023

 
AANW ANAESTHETICS LIMITED
 
 
  
REPORT TO THE DIRECTORS ON THE PREPARATION OF THE UNAUDITED STATUTORY FINANCIAL STATEMENTS OF AANW ANAESTHETICS LIMITED
FOR THE YEAR ENDED 31 JULY 2023

In order to assist you to fulfil your duties under the Companies Act 2006, we have prepared for your approval the financial statements of AANW Anaesthetics Limited for the year ended 31 July 2023 which comprise the Balance sheet and the related notes from the Company's accounting records and from information and explanations you have given us.

As a practising member firm of the Association of Chartered Certified Accountantswe are subject to its ethical and other professional requirements which are detailed at https://www.accaglobal .com/uk/en/about-us /regulation/ethics /acca-rulebook.html.

This report is made solely to the Board of directors of AANW Anaesthetics Limited, as a body, in accordance with the terms of our engagement letter. Our work has been undertaken solely to prepare for your approval the financial statements of AANW Anaesthetics Limited and state those matters that we have agreed to state to the Board of directors of AANW Anaesthetics Limited, as a body, in this report in accordance with the requirements of the Association of Chartered Certified Accountants as detailed at http://www.accaglobal .com/content/dam/ACCA_Global /Technical /fact/technical-factsheet -163.pdf. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than AANW Anaesthetics Limited and its Board of directors, as a body, for our work or for this report. 

It is your duty to ensure that AANW Anaesthetics Limited has kept adequate accounting records and to prepare statutory financial statements that give a true and fair view of the assets, liabilities, financial position and profit of AANW Anaesthetics Limited. You consider that AANW Anaesthetics Limited is exempt from the statutory audit requirement for the year.

We have not been instructed to carry out an audit or review of the financial statements of AANW Anaesthetics Limited. For this reason, we have not verified the accuracy or completeness of the accounting records or information and explanations you have given to us and we do not, therefore, express any opinion on the statutory financial statements.

  


Wellers
Accountants
8 King Edward Street
Oxford
OX1 4HL
29 July 2024
Page 1

 
AANW ANAESTHETICS LIMITED
REGISTERED NUMBER: 12118523

BALANCE SHEET
AS AT 31 JULY 2023

2023
2022
Note
£
£

  

Current assets
  

Cash at bank and in hand
 5 
7,754
8,068

  
7,754
8,068

Creditors: amounts falling due within one year
 6 
(5,289)
(7,529)

Net current assets
  
 
 
2,465
 
 
539

Total assets less current liabilities
  
2,465
539

  

Net assets
  
2,465
539


Capital and reserves
  

Called up share capital 
  
100
100

Profit and loss account
  
2,365
439

  
2,465
539


Page 2

 
AANW ANAESTHETICS LIMITED
REGISTERED NUMBER: 12118523
    
BALANCE SHEET (CONTINUED)
AS AT 31 JULY 2023

The directors consider that the Company is entitled to exemption from audit under section 477 of the Companies Act 2006 and members have not required the Company to obtain an audit for the year in question in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with the provisions of FRS 102 Section 1A - small entities.

The financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The Company has opted not to file the statement of income and retained earnings in accordance with provisions applicable to companies subject to the small companies' regime.

The financial statements were approved and authorised for issue by the board and were signed on its behalf by: 




................................................
Dr A J Ankers
................................................
Ms N Wakefield
Director
Director


Date: 26 July 2024

The notes on pages 4 to 7 form part of these financial statements.

Page 3

 
AANW ANAESTHETICS LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 JULY 2023

1.


General information

AANW Anaesthetics Limited is a private limited company limited by share capital, incorporated in England and Wales.
The Company’s registration number is 12118523.
The address of the registered office is 8 King Edward Street, Oxford, England, OX1 4HL.

2.Accounting policies

 
2.1

Basis of preparation of financial statements

The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with FRS 102 'The Financial Reporting Standard applicable in the UK and the Republic of Ireland' and the requirements of the Companies Act 2006. The disclosure requirements of Section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The following principal accounting policies have been applied:

 
2.2

Revenue

Revenue is recognised to the extent that it is probable that the economic benefits will flow to the Company and the revenue can be reliably measured. Revenue is measured as the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes. The following criteria must also be met before revenue is recognised:

Rendering of services

Revenue from a contract to provide services is recognised in the period in which the services are provided in accordance with the stage of completion of the contract when all of the following conditions are satisfied:
the amount of revenue can be measured reliably;
it is probable that the Company will receive the consideration due under the contract;
the stage of completion of the contract at the end of the reporting period can be measured reliably; and
the costs incurred and the costs to complete the contract can be measured reliably.

 
2.3

Interest income

Interest income is recognised in profit or loss using the effective interest method.

 
2.4

Taxation

Tax is recognised in profit or loss except that a charge attributable to an item of income and expense recognised as other comprehensive income or to an item recognised directly in equity is also recognised in other comprehensive income or directly in equity respectively.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the balance sheet date in the countries where the Company operates and generates income.

Page 4

 
AANW ANAESTHETICS LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 JULY 2023

2.Accounting policies (continued)

 
2.5

Cash and cash equivalents

Cash is represented by cash in hand and deposits with financial institutions repayable without penalty on notice of not more than 24 hours. Cash equivalents are highly liquid investments that mature in no more than three months from the date of acquisition and that are readily convertible to known amounts of cash with insignificant risk of change in value.

 
2.6

Creditors

Short-term creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method.

 
2.7

Financial instruments

The Company has elected to apply the provisions of Section 11 “Basic Financial Instruments” of FRS 102 to all of its financial instruments.

Basic financial assets

Basic financial assets, which include trade and other receivables, cash and bank balances, are initially measured at their transaction price including transaction costs and are subsequently carried at their amortised cost using the effective interest method, less any provision for impairment, unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest.

Discounting is omitted where the effect of discounting is immaterial. The Company's cash and cash equivalents, trade and most other receivables due with the operating cycle fall into this category of financial instruments.

Financial liabilities

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instruments any contract that evidences a residual interest in the assets of the Company after the deduction of all its liabilities.

Basic financial liabilities, which include trade and other payables, bank loans and other loans are initially measured at their transaction price after transaction costs. When this constitutes a financing transaction, whereby the debt instrument is measured at the present value of the future receipts discounted at a market rate of interest. Discounting is omitted where the effect of discounting is immaterial.

Debt instruments are subsequently carried at their amortised cost using the effective interest rate method.

Trade payables are obligations to pay for goods and services that have been acquired in the ordinary course of business from suppliers. Trade payables are classified as current liabilities if the payment is due within one year. If not, they represent non-current liabilities. Trade payables are initially recognised at their transaction price and subsequently are measured at amortised cost using the effective interest method. Discounting is omitted where the effect of discounting is immaterial.

Page 5

 
AANW ANAESTHETICS LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 JULY 2023

2.Accounting policies (continued)

 
2.8

Dividends

Equity dividends are recognised when they become legally payable. Interim equity dividends are recognised when paid. Final equity dividends are recognised when approved by the shareholders at an annual general meeting.


3.


Employees

2023
£

Wages and salaries
9,060

Social security costs
26

9,086


The average monthly number of employees, including directors, during the year was 2 (2022 - 2).


4.


Debtors


5.


Cash and cash equivalents

2023
2022
£
£

Cash at bank and in hand
7,754
8,068

7,754
8,068



6.


Creditors: Amounts falling due within one year

2023
2022
£
£

Corporation tax
921
438

Other taxation and social security
142
303

Other creditors
2,726
5,288

Accruals and deferred income
1,500
1,500

5,289
7,529


Page 6

 
AANW ANAESTHETICS LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 JULY 2023

7.


Controlling party

The ultimate controlling party is Dr A J Ankers by virtue of his majority shareholding.

 
Page 7